Vimarsana
Biggest News Aggregation in the World

Page 6 - Specific Populations News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Specific Populations. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Specific Populations Today - Breaking & Trending Today

Data Demonstrating Financial Impact of INPEFA® (Sotagliflozin) to be Presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting - Lexicon Pharmaceuticals (NASDAQ:LXRX) - Vimarsana News

Data Demonstrating Financial Impact of INPEFA® (Sotagliflozin) to be Presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting - Lexicon Pharmaceuticals (NASDAQ:LXRX)

Studies address cost-effectiveness and budget impact of INPEFA, an inhibitor of SGLT2 and SGLT1 INPEFA recently approved by FDA for treatment of heart failure Abstracts published in the Journal of Managed Care &

EMD Serono Presents New MAVENCLAD® (Cladribine) Tablets Data Highlighting Sustained Reduction in NfLs and Benefit of Early Initiation - Vimarsana News

EMD Serono Presents New MAVENCLAD® (Cladribine) Tablets Data Highlighting Sustained Reduction in NfLs and Benefit of Early Initiation

ROCKLAND, Mass., October 10, 2023--EMD Serono, the Healthcare business sector of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced the presentation of new analyses from the MAVENCLAD® (cladribine) tablets MAGNIFY-MS study, which demonstrated that patients with relapsing multiple sclerosis (RMS) experienced sustained reduction in serum neurofilament light chain (NfL), indicating that MAVENCLAD reduced neuronal injury over two years. Additional data include two real-world evi

Source: yahoo.com
60 Degrees Pharma Withdraws COVID Phase IIB IND, Will Resubmit Pending Assessment of Ability to Meet FDA Requirements - 60 Degrees (NASDAQ:SXTP), 60 Degrees (NASDAQ:SXTPW) - Vimarsana News

60 Degrees Pharma Withdraws COVID Phase IIB IND, Will Resubmit Pending Assessment of Ability to Meet FDA Requirements - 60 Degrees (NASDAQ:SXTP), 60 Degrees (NASDAQ:SXTPW)

Prompted by advice from FDA regarding study design, 60P Australia Pty Ltd, a majority-owned subsidiary of 60 Degrees Pharmaceuticals, has withdrawn its IND for ACLR8-LR, a Phase IIB study of the use of tafenoquine in

60 Degrees Pharma Withdraws COVID Phase IIB IND, Will - Vimarsana News

60 Degrees Pharma Withdraws COVID Phase IIB IND, Will

Prompted by advice from FDA regarding study design, 60P Australia Pty Ltd, a majority-owned subsidiary of 60 Degrees Pharmaceuticals, has withdrawn its IND...

60 Degrees Pharmaceuticals Study Results Published by New Microbes and New Infections Demonstrate Tafenoquine Exhibits Broad Spectrum Antifungal Activity - Vimarsana News

60 Degrees Pharmaceuticals Study Results Published by New Microbes and New Infections Demonstrate Tafenoquine Exhibits Broad Spectrum Antifungal Activity

Data showed tafenoquine does not exhibit cross-susceptibility with fluconazole against Candida spp.Effective treatment of drug-resistant Candida infections is an unmet need in U.S. marketPresumed mode...